L3VLUP
ProSign in

NVCR · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVCRJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVCR
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterNVCRJNJ
Q3 202010 holders, $3.0bn30 holders, $26.2bn
Q4 20208 holders, $4.6bn32 holders, $26.6bn
Q1 20217 holders, $3.7bn31 holders, $25.3bn
Q2 20218 holders, $7.3bn37 holders, $25.6bn
Q3 20218 holders, $3.6bn40 holders, $24.1bn
Q4 20216 holders, $2.3bn33 holders, $25.2bn
Q1 20225 holders, $2.7bn35 holders, $28.2bn
Q2 20229 holders, $2.4bn33 holders, $26.9bn
Q3 20226 holders, $3.0bn36 holders, $25.4bn
Q4 20226 holders, $2.9bn35 holders, $27.6bn
Q1 20237 holders, $2.5bn42 holders, $24.5bn
Q2 20237 holders, $1.6bn38 holders, $25.0bn
Q3 20238 holders, $329m37 holders, $18.9bn
Q4 202310 holders, $205m31 holders, $19.0bn
Q1 20249 holders, $145m32 holders, $19.7bn
Q2 20247 holders, $145m35 holders, $20.4bn
Q3 20247 holders, $142m28 holders, $22.3bn
Q4 20248 holders, $758m37 holders, $20.4bn
Q1 20256 holders, $198m32 holders, $20.5bn
Q2 20254 holders, $187m31 holders, $18.4bn
Q3 20253 holders, $43m32 holders, $23.7bn
Q4 20253 holders, $18m29 holders, $27.8bn
Q1 20262 holders, $12m34 holders, $35.6bn
Q2 20262 holders, $15m33 holders, $39.1bn
NVCR

Novocure Ltd

Holders
8
Reported value
$758m
Buyers
2
Sellers
5

Breadth -3 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
JNJ

Johnson & Johnson

Holders
37
Reported value
$20.4bn
Buyers
23
Sellers
12

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 41 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NVCR (4)

Baillie Gifford & Co, Capital World Investors, Coatue Management LLC, PDT Partners LLC

Only JNJ (33)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Quantbot Technologies LP, and 8 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →